NCT07821229Active, not recruiting
Combination of Mitomycin and Carboplatin in Neoadjuvant Therapy in BRCA-associated Triple-negative Locally Advanced Breast Cancer
Use of a Combination of Mitomycin and Carboplatin in Neoadjuvant Therapy in Patients With BRCA-associated Triple-negative Locally Advanced Breast Cancer
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
This study was designed to evaluate the safety and efficacy of neoadjuvant therapy with mitomycin and carboplatin in patients with BRCA-associated locally advanced triple-negative breast cancer.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 6 May 2026
- Start date
- 27 Sept 2022
- Primary completion date
- 1 Dec 2030
- Lead sponsor
- N.N. Petrov National Medical Research Center of Oncology
- Diseases
- Metastatic breast cancer
- NCT number
- NCT07821229
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 27 Sept 2022 to the primary completion date, 1 Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior administration of any systemic therapy for breast cancer;
- Presence of a second malignant tumor (except for previously cured malignancies);
Other illness
- Stage IV disease;
- Severe uncontrolled chronic comorbidities or acute illnesses;
Age
- Age \> 70 years;
Other
- Renal dysfunction;
- Pregnancy or breastfeeding;
- Negative molecular genetic test for BRCA1\|2 gene mutation
Who the study is looking for
- Signed informed consent to participate in the study;
- Histopathological confirmation of triple-negative breast cancer;
- Stage: clinical T1-T4, N0-3, M0;
- Positive molecular genetic test for BRCA1\|2 gene mutation (PCR test or NGS result);
- Age \> 18 years;
- ECOG status 0-1.
Age in the registry: 18 years to 70 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| N.N. Petrov National Medical Research Center of Oncology Coordinator of this site? Confirm its status | Saint Petersburg | Russia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.